These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30806330)

  • 1. Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.
    Aboelnaga MM; Eladawy EH; Elshafei MM; Abdullah N; Shaer ME
    Endocr Metab Immune Disord Drug Targets; 2019; 19(4):511-518. PubMed ID: 30806330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
    Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
    Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
    Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas.
    Auriemma RS; Galdiero M; Vitale P; Granieri L; Lo Calzo F; Salzano C; Ferreri L; Pivonello C; Cariati F; Coppola G; de Angelis C; Colao A; Pivonello R
    Neuroendocrinology; 2015; 101(1):66-81. PubMed ID: 25592453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.
    Berinder K; Nyström T; Höybye C; Hall K; Hulting AL
    Pituitary; 2011 Sep; 14(3):199-207. PubMed ID: 21128120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
    Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
    Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study.
    Posawetz AS; Trummer C; Pandis M; Aberer F; Pieber TR; Obermayer-Pietsch B; Pilz S; Theiler-Schwetz V
    BMC Endocr Disord; 2021 Apr; 21(1):81. PubMed ID: 33902531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
    dos Santos Silva CM; Barbosa FR; Lima GA; Warszawski L; Fontes R; Domingues RC; Gadelha MR
    Obesity (Silver Spring); 2011 Apr; 19(4):800-5. PubMed ID: 20559294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of dopamine-agonists treatment among patients with prolactinomas.
    Kabootari M; Shirmohammadli H; Golgiri F; Mosalamiaghili S; Khajavi A; Akbari H
    Endocrine; 2023 Mar; 79(3):537-544. PubMed ID: 36352337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
    Portari LHC; Correa-Silva SR; Abucham J
    Neuroendocrinology; 2022; 112(1):68-73. PubMed ID: 33477154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
    Buyukbayrak EE; Karageyim Karsidag AY; Kars B; Balcik O; Pirimoglu M; Unal O; Turan C
    Arch Gynecol Obstet; 2010 Nov; 282(5):561-6. PubMed ID: 20571820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline.
    Pala NA; Laway BA; Misgar RA; Dar RA
    Diabetol Metab Syndr; 2015; 7():99. PubMed ID: 26583049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
    Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cabergoline on metabolism in prolactinomas.
    Auriemma RS; Granieri L; Galdiero M; Simeoli C; Perone Y; Vitale P; Pivonello C; Negri M; Mannarino T; Giordano C; Gasperi M; Colao A; Pivonello R
    Neuroendocrinology; 2013; 98(4):299-310. PubMed ID: 24355865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hyperprolactinemia: A single-institute experience.
    Chen TY; Lee CH; Yang MY; Shen CC; Yang YP; Chien Y; Huang YF; Lai CM; Cheng WY
    J Chin Med Assoc; 2021 Nov; 84(11):1019-1022. PubMed ID: 34261980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperprolactinemia in the postmenopause: versions and contraversions].
    Leshchenko OY
    Ter Arkh; 2021 Oct; 93(10):1234-1239. PubMed ID: 36286827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of obstructive sleep apnea in patients with prolactinoma before and after treatment with dopamine agonists.
    Barbosa FR; Silva CM; Lima GA; Warszawski L; Domingues RC; Dominic M; Fontes R; Vieira Neto L; Gadelha MR
    Pituitary; 2014 Oct; 17(5):441-9. PubMed ID: 24068456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
    Hu J; Zheng X; Zhang W; Yang H
    Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.